BIOCELTIX S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.5 PLN | +4.63% |
|
-2.24% | -27.22% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 372M 1.48B |
|---|---|---|---|---|---|
| Net income 2022 | -8M -31.96M | Net income 2023 | -13M -51.93M | EV / Sales 2022 | - |
| Net cash position 2022 | 3.83M 15.28M | Net cash position 2023 | 9.31M 37.19M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-14.5
x | P/E ratio 2023 |
-25.8
x | Employees | 26 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 67.46% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.63% | ||
| 1 week | -2.24% | ||
| Current month | -2.53% | ||
| 1 month | -8.65% | ||
| 3 months | -26.57% | ||
| 6 months | +7.03% | ||
| Current year | -27.22% |
1 week
60.20
69.50
1 month
60.2073.70
Current year
60.2098.00
1 year
58.4098.00
3 years
28.7098.00
5 years
28.7098.00
10 years
28.7098.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 41 | 18-08-12 | |
Andrij Wlach
DFI | Director of Finance/CFO | 40 | - |
Elzbieta Gocek
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 65.5 | +4.63% | 4,673 |
| 24-05-09 | 62.6 | -2.19% | 6,065 |
| 24-05-08 | 64 | -3.61% | 16,328 |
| 24-05-07 | 66.4 | -0.90% | 2,748 |
| 24-05-06 | 67 | 0.00% | 1,731 |
Delayed Quote Warsaw S.E., May 10, 2024 at 11:55 am EDT
More quotes
Bioceltix SA is a Poland-based biopharmaceutical company, which operates in the field of veterinary medicine. The Company deal with the development of candidates for veterinary medicinal products based on the immunomodulatory properties of mesenchymal stem cells used as the active substance of the drug. Entity's products are intended for the treatment of companion animals. The Company carry out research and development works, which enable clinical trials and full registration of medicinal products in the European Medicines Agency, as is the case with medicines and drugs administered to humans.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -27.22% | 67.74M | |
| -14.35% | 77.13B | |
| +14.09% | 8.4B | |
| +27.62% | 3.79B | |
| -0.70% | 3.22B | |
| +14.70% | 1.64B | |
| -10.12% | 1.5B | |
| -22.60% | 1.3B | |
| -4.20% | 1.25B | |
| -10.26% | 1.18B |
- Stock Market
- Equities
- BCX Stock
